Contribution: Industrial Research Assistance Program – Contributions to Firms
General Intermediates of Canada Inc.
$233,000.00
Synthetic nucleosides as new pharmaceuticals
EF 2018-19 · 2018-07-01
Résumé
The proposed project involves Stage 1 drug discovery program on synthetic anticancer nucleosides based on Firm's existing technology platform in nucleoside chemistry including a library of nucleoside based molecules, many of which have been of interest to the pharmaceutical industry. Objective is to develop and screen a series of synthetic nucleosides, identify lead candidates and fully characterize them for anticancer properties on human cancer cell lines. Ultimate goal is to discover proprietary anticancer drug candidate/s with high therapeutic index for consideration as a pharmaceutical within the synthetic anticancer nucleosides drug class.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Edmonton|Edmonton, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
134132257
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2018-07-01 | 2018-19 | $233,000.00 |
| 1 | 2018-07-01 | 2018-19 | $233,000.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 60 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 60 jours.
Agreement End Date
2020-02-29
Agreement Number
909375
Agreement Start Date
2018-07-01
Agreement Title
Synthetic nucleosides as new pharmaceuticals
Agreement Title (French)
Nucléosides synthétiques en tant que nouveaux produits pharmaceutiques
Agreement Type
Contribution
Agreement Value
$233,000.00
Amendment Date
2019-02-07
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The proposed project involves Stage 1 drug discovery program on synthetic anticancer nucleosides based on Firm's existing technology platform in nucleoside chemistry including a library of nucleoside based molecules, many of which have been of interest to the pharmaceutical industry. Objective is to develop and screen a series of synthetic nucleosides, identify lead candidates and fully characterize them for anticancer properties on human cancer cell lines. Ultimate goal is to discover proprietary anticancer drug candidate/s with high therapeutic index for consideration as a pharmaceutical within the synthetic anticancer nucleosides drug class.
Description (French)
Pour le premier stade, le projet proposé comprend un programme de découverte de médicaments sur des nucléosides anticancéreux synthétiques basé sur la plate-forme technologique existante de l'entreprise en chimie des nucléosides, comprenant une bibliothèque de molécules à base de nucléosides, dont beaucoup intéressent l'industrie pharmaceutique. L'objectif est de développer et de cribler une série de nucléosides synthétiques, d'identifier des candidats principaux et de les caractériser complètement pour des propriétés anticancéreuses sur des lignées cellulaires cancéreuses humaines. Le but ultime est de découvrir un ou plusieurs médicaments anticancéreux candidats possédant un indice thérapeutique élevé, à prendre en considération en tant que médicament dans la classe des médicaments nucléosides anticancéreux synthétiques.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton West
Federal Riding (French)
Edmonton-Ouest
Federal Riding Number
48020
NAICS Code
325999
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
134132257
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
General Intermediates of Canada Inc.
Recipient Postal Code
T5S 1G2
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2018-2019-Q2-909375
